Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 24 Late-Breaking Discussion: The FLOW Trial
Author(s): Harriette Van Spall , Added: 1 year ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ADA 2025 Late-Breaking Science Collection
Author(s): Sue Pedersen Added: 11 months ago
Watch Expert Interviews sharing the late-breaking trial data from the American Diabetes Association's Scientific Sessions 2025. View more

Cardiovascular Kidney Metabolic
Novo Nordisk
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries, and markets its… View more
Comparison of the Prevalence of Hypertension Using Three Proposed Criteria
Author(s): Kristina Marie Michelle O Rivera , Lucky Cuenza Added: 2 months ago

Prevention & Chronic Conditions

Guidelines & Statements
Integrating New Weight Management Therapies into Comprehensive CVD Care
Author(s): Steven E Nissen Added: 1 year ago
Is BMI the best indicator to identify CVD patients who can be treated with GLP-1 RAs and other weight management therapies?In this short interview, Dr Steven Nissen (Cleveland Clinic, Cleveland, US) discusses how to determine which CVD patients will benefit most from treatment with GLP-1 RAs. He highlights how lifestyle changes are often ineffective in achieving weight loss goals, and therefore,… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Semaglutide May Aid Vascular Repair in High-Risk Patients
Added: 2 months ago Source:  Radcliffe CVRM
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce major atherosclerotic cardiovascular events, but the full extent of their mechanisms is still being explored. The SEMA-VR CardioLink-15 trial investigated whether semaglutide affects the levels of circulating vascular regenerative (VR) cells, which are involved in vessel repair and may modulate atherothrombotic risk.¹… View more

Cardiovascular Kidney Metabolic
The Role of GLP-1 in Heart Failure
Author(s): Amina Rakisheva , Anton Zatsarinnyy Added: 4 months ago

Inherited and Congenital Cardiac Conditions

Heart Failure
William Herrington
Research Area(s) / Expertise: Job title: Professor of Trials and Epidemiology of Kidney Disease
Professor William Herrington is an Honorary Consultant Nephrologist at Oxford Kidney Unit and the Professor of Trials and Epidemiology of Kidney Disease at the Nuffield Department of Population Health, University of Oxford.Prof Herrington earned his MD from the University of Cambridge in 2013, focusing on the impact of lowering LDL cholesterol on stroke in chronic kidney disease.He has previously… View more
Bariatric Surgery: Reduced CVD Risk via PREVENT Equations
Author(s): Danxia Yu Added: 1 year ago
Outcomes from a new CV disease risk assessment tool show significant improvements in CV, kidney and metabolic health after bariatric surgery. The study also found a reduction in estimated 10 year risk of developing total CV disease and a reduction in the risk of developing heart failure one year after bariatric surgery.In this short interview, Dr Danxia Yu (Vanderbilt University Medical Center,… View more

Cardiovascular Kidney Metabolic

Prevention & Chronic Conditions
Research Area(s) / Expertise: Job title: Professor
Tina Vilsbøllis a Clinical Professor and Head of Clinic at Steno Diabetes Center, Copenhagen, Denmark. She has been involved in diabetes research since 1997 and in 2004 she established the Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark, now part of Steno Diabetes Centre Copenhagen. Her research is focused on the pathophysiology of obesity, prediabetes,… View more